Clinical trial
The Study of Atherosclerosis With Ramipril and Rosiglitazone
NCT00140647 · Gerstein, Hertzel, MD, Other · Completed
Key facts
| NCT number | NCT00140647 |
|---|---|
| Title | The Study of Atherosclerosis With Ramipril and Rosiglitazone |
| Official title | The Study of Atherosclerosis With Ramipril and Rosiglitazone |
| Lead sponsor | Gerstein, Hertzel, MD, Other |
| Collaborators | Heart and Stroke Foundation of Ontario |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atherosclerosis, Impaired Glucose Tolerance, Isolated Impaired Fasting Glucose, Cardiovascular Disease |
| Intervention type | Drug |
| Interventions | Ramipril, Rosiglitazone |
| Enrollment | 1,200 |
| Start date | Jul 1, 2001 |
| Completion | Jul 1, 2006 |
| First posted | Sep 1, 2005 |
| Last update posted | Aug 25, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: